-- 美國經濟諮商局的領先指標3月下降0.6%,低於彭博社調查預期的0.2%的降幅,而2月則上漲了0.3%。 10個組成部分中有5個對該指標產生了負面影響,尤其是建築許可、商業預期和股價。其餘5個組成部分則產生了較小的正面影響,特別是非國防資本貨物新訂單。 「美國領先指標在2月上漲後,3月大幅回落,原因是建築許可下降,消費者預期和股價走弱,」美國經濟諮商局商業週期指標高級經理尤斯蒂娜·扎賓斯卡-拉莫尼卡表示。 “領先指標繼續顯示,未來幾個月經濟將放緩,因為油價上漲和供應鏈緊張局勢可能會進一步推高通膨,並進一步降低消費者的購買力。”
Related Articles
Alignment Healthcare Swings to Q1 Profit, Revenue Rises; Shares Fall After Hours
Alignment Healthcare (ALHC) reported Q1 earnings late Thursday of $0.05 per diluted share, compared with the loss of $0.05 a year earlier.Analysts polled by FactSet expected earnings of $0.01.Revenue in the three months ended March 31 rose to $1.24 billion from $926.9 million a year ago.Analysts surveyed by FactSet expected $1.22 billion.The company expects revenue of $1.3 billion to $1.32 billion in Q2 and $5.16 billion to $5.21 billion in the full year.Analysts project $1.31 billion in Q2 and $5.17 billion in 2026.Alignment Healthcare shares fell 10% in after-hours trading.
Research Alert: Columbia Sportswear Company Beats Estimates; Raises Full-year Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:COLM posted Q1 2026 EPS of $0.65 vs. $0.75 prior year, $0.30 above consensus on flat net sales of $779M, $21M above estimates. International diversification proved valuable with EMEA surging 35% and LAAP growing 5%, offsetting a 10% U.S. decline, while gross margin contracted 20 bps to 50.7% primarily from a 310-bp incremental tariff impact. We believe the international growth strategy is effectively insulating the company from U.S. tariff headwinds and positioning it for sustained global expansion. Management raised full-year EPS guidance to $3.55-$4.00 from prior $3.20-$3.65 and operating margin guidance to 6.7%-7.5% reflecting better tariff conditions. The company maintains its fortress balance sheet with $535.4M cash and no debt while executing a $150M share repurchase program. We are impressed with international performance driving growth and expect continued momentum from the ACCELERATE Growth Strategy targeting younger consumers, with shares trading at 17x forward EPS guidance.